| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 13.55▲ | 8.76▲ | 8.76▲ | 4.15▲ | 4.27▲ |
| MA10 | 8.82▲ | 6.53▲ | 6.53▲ | 2.66▲ | 4.10▲ |
| MA20 | 6.67▲ | 5.64▲ | 5.62▲ | 2.17▲ | 4.96▲ |
| MA50 | 5.58▲ | 5.23▲ | 5.31▲ | 3.83▲ | 4.72▲ |
| MA100 | 5.43▲ | 5.23▲ | 5.25▲ | 4.69▲ | 8.96▲ |
| MA200 | 5.23▲ | 5.36▲ | 5.58▲ | 4.96▲ | 56.07▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 1.453▲ | 1.168▲ | 1.172▲ | 1.070▲ | 0.570▲ |
| RSI | 89.762▲ | 94.675▲ | 94.213▲ | 91.281▲ | 74.630▲ |
| STOCH | 66.633 | 32.876 | 32.876 | 31.470 | 19.262▼ |
| WILL %R | -1.446▲ | -1.446▲ | -1.446▲ | -1.167▲ | -1.167▲ |
| CCI | 120.538▲ | 237.649▲ | 237.649▲ | 466.667▲ | 340.723▲ |
| ▲ PSAR&MOM | $ELOX PSAR Switch Up + Momentum | Set Alert |
| ▲ RSI | $ELOX RSI(14) Crossed Above 70 | Set Alert |
| RSI | $ELOX RSI(14) Crossed Above 50 | Set Alert |
| ▲ RSI | $ELOX RSI(14) Crossed Above 30 | Set Alert |
| ▲ MACD | $ELOX MACD(12,26,9) Crossed Above Zero | Set Alert |
| MA | $ELOX Price Crossed Above MA(200) | Set Alert |
| MA | $ELOX Price Crossed Above MA(50) | Set Alert |
| MA | $ELOX Price Crossed Above MA(26) | Set Alert |
| MA | $ELOX Price Crossed Above MA(13) | Set Alert |
| ▲ GAP | $ELOX Open Gap Up %5 | Set Alert |
| ▲ GAP | $ELOX Open Gap Up %3 | Set Alert |
| ▲ GAP | $ELOX Open Gap Up %2 | Set Alert |
| ▲ BREAK | $ELOX Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $ELOX Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $ELOX Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $ELOX Price Breaks 10 Days High | Set Alert |
|
Monday, June 08, 2026 06:37 PM
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) ("Eloxx" and the "Company"), a clinical-stage biopharmaceutical company developing novel, small molecule product candidates designed to modulate the ribosome ...
|
|
Monday, June 08, 2026 05:00 PM
City Therapeutics’ Series B syndicate added Viking Global and Sofinnova, with continued support from multiple crossover and strategic investors, signaling broad buy-side confidence in RNAi platform ...
|
|
Thursday, August 03, 2023 07:26 AM
WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/06/26 | 15.49 | 16.42 | 15.49 | 16.24 | 17,038 |
| 17/11/23 | 1.15 | 1.24 | 1.1302 | 1.15 | 8,314 |
| 15/11/23 | 1.11 | 1.20 | 1.00 | 1.10 | 32,884 |
| 14/11/23 | 1.193 | 1.20 | 1.04 | 1.10 | 16,892 |
| 13/11/23 | 1.20 | 1.24 | 1.17 | 1.18 | 3,829 |
| 10/11/23 | 1.14 | 1.29 | 1.13 | 1.185 | 7,153 |
| 08/11/23 | 1.05 | 1.10 | 1.01 | 1.093 | 22,648 |
| 07/11/23 | 1.28 | 1.29 | 1.05 | 1.07 | 40,625 |
| 06/11/23 | 1.50 | 1.50 | 1.22 | 1.22 | 29,661 |
| 03/11/23 | 1.27 | 1.31 | 1.25 | 1.28 | 27,732 |
|
|
||||
|
|
||||
|
|